Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
13
02
2020
accepted:
29
03
2020
pubmed:
30
5
2020
medline:
15
12
2020
entrez:
30
5
2020
Statut:
ppublish
Résumé
The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (<7 mm, 76.6%), and bifurcation aneurysm location (basilar apex, 28.9%; anterior communicating artery, 27.3%; and middle cerebral artery bifurcation, 12.5%) were common. A single stent was used in 92.2% of cases, and a single catheter for both stent placement and coiling was used in 59.4% of cases. Technical complications during stent deployment occurred in 4.7% of cases; symptomatic thromboembolic stroke, in 2.3%; and symptomatic hemorrhage, in 0.8%. Favorable Raymond grades (Raymond-Roy occlusion classification) I and II were achieved in 82.9% at discharge and 89.5% at last follow-up. mRS ≤2 was determined in 96.9% of patients at last follow-up. The immediate Raymond-Roy occlusion classification grade correlated with aneurysm location ( This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.
Sections du résumé
BACKGROUND AND PURPOSE
The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent.
MATERIALS AND METHODS
On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up.
RESULTS
Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (<7 mm, 76.6%), and bifurcation aneurysm location (basilar apex, 28.9%; anterior communicating artery, 27.3%; and middle cerebral artery bifurcation, 12.5%) were common. A single stent was used in 92.2% of cases, and a single catheter for both stent placement and coiling was used in 59.4% of cases. Technical complications during stent deployment occurred in 4.7% of cases; symptomatic thromboembolic stroke, in 2.3%; and symptomatic hemorrhage, in 0.8%. Favorable Raymond grades (Raymond-Roy occlusion classification) I and II were achieved in 82.9% at discharge and 89.5% at last follow-up. mRS ≤2 was determined in 96.9% of patients at last follow-up. The immediate Raymond-Roy occlusion classification grade correlated with aneurysm location (
CONCLUSIONS
This multicenter analysis provides a real-world safety and efficacy profile for the treatment of intracranial aneurysms with the Neuroform Atlas stent.
Identifiants
pubmed: 32467183
pii: ajnr.A6581
doi: 10.3174/ajnr.A6581
pmc: PMC7342754
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1042Subventions
Organisme : NINDS NIH HHS
ID : R21 NS109575
Pays : United States
Informations de copyright
© 2020 by American Journal of Neuroradiology.
Références
AJNR Am J Neuroradiol. 2015 Oct;36(10):1934-41
pubmed: 26021624
J Neurointerv Surg. 2019 Aug;11(8):801-806
pubmed: 30670625
J Neurointerv Surg. 2017 Sep;9(9):854-859
pubmed: 27557944
Neurosurgery. 2013 Mar;72(3):415-27
pubmed: 23208060
Neurosurgery. 2019 Jan 1;84(1):179-189
pubmed: 29579261
J Neurointerv Surg. 2018 Dec;10(12):1192-1196
pubmed: 29678886
Clin Neuroradiol. 2020 Jan 22;:
pubmed: 31970465
Neuroradiology. 2018 Feb;60(2):211-219
pubmed: 29273960
J Neurol Sci. 2016 May 15;364:160-6
pubmed: 27084238
J Neurointerv Surg. 2019 Feb;11(2):171-174
pubmed: 30077966
J Neurointerv Surg. 2015 Jul;7(7):496-502
pubmed: 24898735
Interv Neuroradiol. 2019 Oct;25(5):521-529
pubmed: 30939955
J Neurosurg. 2018 Apr 27;130(3):895-901
pubmed: 29701554
J Neurointerv Surg. 2019 Nov;11(11):1141-1144
pubmed: 30979847
Interv Neuroradiol. 2018 Jun;24(3):263-269
pubmed: 29350091
J Neuroradiol. 2019 Apr 2;:
pubmed: 30951769
AJNR Am J Neuroradiol. 2015 Feb;36(2):323-9
pubmed: 25234031